Comparison of Ebastine and Cetirizine for relief of symptoms in patients with perennial allergic rhinitis

A Comparative Study Of Efficacy, Quality of life And Tolerability Of Ebastine With Cetirizine In Patients Of Perennial Allergic Rhinitis At Tertiary Care Hospital - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/110524

Enrollment

130

Registered

2026-05-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J301- Allergic rhinitis due to pollen

Interventions

Intervention1: EBASTINE: Patients will receive oral EBASTINE 20mg tablet orally once daily for 4 weeks duration. Control Intervention1: CETIRIZINE: Patients will receive oral CETIRIZINE 10mg tablet or

Eligibility

Inclusion criteria

Inclusion criteria: 1] Male and Female patients aged between 18 and 65 years with a clinical diagnosis of mild to moderate - severe intermittent or perennial allergic rhinitis, confirmed by symptoms scores (eg., TNSS or TSS baseline : 5 or 6) 2]Patients who provide informed consent and are able to comply with study procedures, including symptom recording. 3) New and old cases of allergic rhinitis with symptoms history more than 1 year

Exclusion criteria

Exclusion criteria: 1] Non-consenting subjects or those unwilling/unable to comply with study procedures. 2] Patients with comorbid respiratory conditions such as asthma, chronic or acute sinusitis, nasal structural abnormalities (e.g., large nasal polyps or marked septal deviation) 3] those currently using nasal/oral decongestants, nasal steroids, or antihistamines. 4] Pregnant and lactating females.

Design outcomes

Primary

Measure	Time frame
TO compare the efficacy of ebastine against cetirizine in reducing allergic rhinitis symptomsTimepoint: Primary outcome measures will be assessed at baseline before treatmnt initiation, at 2 weeks and at 4 weeks after starting the treatment.	—

Secondary

Measure	Time frame
1] To assess the safety and tolerability profile of ebastine and cetirizine. 2] To compare the adverse effects of ebastine and cetirizine in treatment of allergic rhinitis. 3] To study demographic and clinical factors affecting the treatment response.Timepoint: 4 weeks	—

Countries

India

Contacts

Public ContactDr shrikant Chandrakant Dharmadhikari

Vilasrao Deshmukh Government medical college, latur

shrikantdharmadhikari5@gmail.com9421196246

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026